rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
1
|
pubmed:dateCreated |
1986-7-18
|
pubmed:abstractText |
Several antitumor drugs including DNA intercalative and non intercalative agents induce in vitro and in vivo double-stranded DNA breaks by stabilization of a topoisomerase II-DNA complex. In order to locate cleavage sites in an actively transcribed oncogene, N417 cells, originating from a human small cell lung carcinoma and containing 45-50 copies of c-myc oncogene, were treated with mAMSA, 9 hydroxyellipticine and VM 26. The presence of DNA lesions in c-myc was investigated by Southern blot hybridization with a human c-myc probe. In addition to normal bands, DNA patterns of drug treated-cells revealed the presence of new bands most likely corresponding to topoisomerase II-mediated cleavage as these bands were not found in untreated control DNA and in DNA treated with oAMSA, a biologically inactive stereoisomer of mAMSA. Major cleavage sites induced by drugs in the N417 cell c-myc locus were located in the 5' end of the c-myc exon 1 closely to some DNAse I hypersensitive sites which are assumed to reflect an activity of the gene. Therefore our data suggest that TopoII-mediated drug activity correlates with gene activity.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/9-hydroxyellipticine,
http://linkedlifedata.com/resource/pubmed/chemical/Aminoacridines,
http://linkedlifedata.com/resource/pubmed/chemical/Amsacrine,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/DNA Topoisomerases, Type II,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxyribonuclease I,
http://linkedlifedata.com/resource/pubmed/chemical/Ellipticines,
http://linkedlifedata.com/resource/pubmed/chemical/Intercalating Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Teniposide
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0006-291X
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:day |
29
|
pubmed:volume |
137
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
154-60
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:3013177-Aminoacridines,
pubmed-meshheading:3013177-Amsacrine,
pubmed-meshheading:3013177-Antineoplastic Agents,
pubmed-meshheading:3013177-Cell Line,
pubmed-meshheading:3013177-Chromosome Mapping,
pubmed-meshheading:3013177-DNA, Neoplasm,
pubmed-meshheading:3013177-DNA Topoisomerases, Type II,
pubmed-meshheading:3013177-Deoxyribonuclease I,
pubmed-meshheading:3013177-Ellipticines,
pubmed-meshheading:3013177-Gene Amplification,
pubmed-meshheading:3013177-Gene Expression Regulation,
pubmed-meshheading:3013177-Genes,
pubmed-meshheading:3013177-Humans,
pubmed-meshheading:3013177-Intercalating Agents,
pubmed-meshheading:3013177-Mutation,
pubmed-meshheading:3013177-Proto-Oncogenes,
pubmed-meshheading:3013177-Teniposide
|
pubmed:year |
1986
|
pubmed:articleTitle |
In vivo stimulation by antitumor drugs of the topoisomerase II induced cleavage sites in c-myc protooncogene.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|